Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know

TheMotleyFool

0 0

GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know

GlaxoSmithKline (NYSE: GSK) and Vir Biotechnology (NASDAQ: VIR) recently reported results from a confirmatory study evaluating antibody therapy sotrovimab in treating non-hospitalized COVID-19 patients. In this Motley Fool Live video recorded on June 23, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss what investors should know about these results.

Source Fool.com

Like: 0

GSK

Share